England's cost-effectiveness watchdog has recommended Eli Lilly’s Verzenios treatment as an option for adjuvant treatment of certain forms of breast cancer.
The pharmaceutical firm will work with the health tech company to create a digital therapeutic intended for patients dealing with a breast cancer diagnosis.
Eli Lilly and Company plans to expand its manufacturing footprint in Indiana by investing $2.1bn in two new manufacturing sites at Indiana's LEAP Lebanon Innovation and Research District in Boone County.
A leader from the division of Eli Lilly explains the importance of driving greater trial inclusivity, and why collaboration is vital in making progress.
The pharmaceutical firm has tapped the decentralized research organization in order to help elevate the inclusivity of its oncology trials at all levels.
The US FDA has published an import alert for an Australian manufacturing site of Eli Lilly after the agency found that its Cialis pills were tainted with the active ingredient of another popular ED (erectile dysfunction) drug -- Pfizer’s Viagra.
The FDA has issued Eli Lilly with a warning letter detailing a significant deviation from cGMP at its API production facility in Puerto Rico, which makes ingredients used in Humalog (insulin lispro), a diabetes treatment.
Eli Lilly has agreed to acquire ImClone for $6.5bn and in doing so appears to have snatched the biotech away from Bristol-Myers Squibb (BMS), which first tabled a bid back in July.
The future of Eli Lilly's API manufacturing facility in Lafayette, Indiana has been thrown into doubt by the news the company is considering selling it.
Eli Lilly plans to cut 500 jobs, mainly in manufacturing, as it
attempts to restructure its operations to mitigate against the
losses from inhaled insulin.
Eli Lilly has agreed to fork out $18m (€12.8m) to settle an ongoing
lawsuit with one of its former biotech research partners and in
doing so has avoided a court battle earmarked for next year.
US drug company, Eli Lilly, offered a more encouraging outlook than
was expected forecasting an earnings growth of up to 12 per cent, a
stark contrast to its struggling competitors, who also face generic
competition, drug safety and...
US drug company, Eli Lilly, offered a more encouraging outlook than
was expected forecasting an earnings growth of up to 12 per cent, a
stark contrast to its struggling competitors, who also face generic
competition, drug safety and...
Drug major Eli Lilly has provided a detailed response to a US
congressional committee request for details of how the firm intends
to tackle the issue of drug counterfeiting.
Lilly pulls out the stops to put right non-compliance issues at its
sites in Indianapolis, evading a fine and raising the prospects for
the launch of two pipeline drugs.
